|
|
PVCT Provectus Biopharmaceuticals
|
|
||
Rare Pediatric Disease Designation again...Late last year, GW Pharmaceuticals received a Rare Pediatric Disease Designation from the FDA to treat 2 rare forms of epilepsy in children, LGS and Dravet syndrome. GW Pharmaceuticals purifies CBD oil into pharmaceutical grade CBD. Sound familiar? Purified Rose Bengal into pharmaceutical grade PV-10 anyone? Today, the FDA approved Epidiolex in yet another example of the FDA rushing to get life saving Pediatric drugs to children that are fighting for their lives. Interestingly, although it's "only" purified CBD oil, and even though it's for the treatment of a rare disease, the estimated annual cost of the drug will be approximately $30,000 and expectations show that Epidiolex could produce $1.1 Billion in sales by 2020 and Goldman Sachs is estimating that annual world-wide sales will reach $2.2 Billion by 2025. The FDA's willingness to grant RPDD for promising drugs in order to rapidly deploy them to children needing treatment only strengthens my excitement over POETIC's involvement with PVCT. We could be very close to something every real in the very near future. And another thing, don't let anyone fool you into thinking that PV-10 is simply "red salt". Those people are speaking either from pure ignorance to absolute deception. You can literally purchase CBD oil in several States that do the exact same thing as the purified CBD oil that GW Pharmaceuticals produced. The value of PV-10 will be it's strong showings in clinical trials and FDA validation. It's never once been about how much the drug costs to make or the fact that Rose Bengal can be obtained by the public. Today's news about Epidiolex proves all of those arguments completely false. |
return to message board, top of board |